After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.

Eisai will now take ownership of the Japanese rights to Henlius' differentiated anti-PD-1 therapy, Hetronifly (serplulimab).

PrimeGen US and DT Cloud Star Acquisition have entered a definitive merger agreement at an implied equity value of around $1.5bn.

Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific ...

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...

The guidance, which was published after the European market closed on 3 February, was punished by investors at market open.

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...

GSK is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.

CEPI and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance the preparedness of global vaccine production for pandemic threats and future epidemic.

Despite being saddled with tariffs and lagging behind China and the US, European sites offer biopharma suppliers a chance to diversify.

Aquestive has received a CRL from the FDA regarding its NDA for Anaphylm, which aims to treat type I allergic reactions in patients weighing 30kg or more.

Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.